Yvonne Yamanaka, Ph.D.
Yvonne Yamanaka, Ph.D., is a Principal at venBio Partners with a background in biological engineering and life science company creation. She has served as a board observer for portfolio companies including NFlection Therapeutics, Turning Point Therapeutics (TPTX), Neurogastrx, Aeovian Pharmaceuticals, and Pharvaris. Previously, Dr. Yamanaka was a member of the venture creation team at Flagship Pioneering. Dr. Yamanaka began her research career leading the development of a novel immunotherapy technology at EMD/Merck Serono. Dr. Yamanaka received her Ph.D. in Biological Engineering from MIT, where she was a Siebel Scholar and NSF Graduate Research Fellow, and her B.S.E. in Biomedical Engineering from Duke University, where she was an Angier B. Duke and Goldwater scholar.